Pre-alloHCT CLL-directed therapies
| Pre-alloHCT CLL-directed therapy . | Proportion, % or median (range) . | No. with available data (total N = 65) . |
|---|---|---|
| Lines of therapy | 3 (1-9) | 65 |
| Prior NAs | 1 (1-3) | 65 |
| 2 or more NAs | 38 | 65 |
| Exclusively NAs | 29 | 63 |
| Prior ibrutinib | 82 | 65 |
| Prior venetoclax | 40 | 65 |
| Prior PI3Ki | 20 | 65 |
| Prior chemotherapy | 71 | 63 |
| Ibrutinib: response and reasons for discontinuation | n = 53 | |
| Best response: CR, PR/PR-L, SD, PD | 6, 86, 4, 4 | 50 |
| Months from ibrutinib initiation to next line of therapy | 9 (2-48) | 50 |
| Reasons for discontinuation | 52 | |
| Planned alloHCT | 62 | |
| Progression | 29 | |
| Toxicity | 6 | |
| Other | 3 | |
| Venetoclax: response and reasons for discontinuation | n = 26 | |
| Best response: CR, PR/PR-L, SD, PD | 50, 42, 4, 4 | 24 |
| Months from venetoclax initiation to next line of therapy | 6 (1-38) | 24 |
| Reasons for discontinuation | 24 | |
| Planned alloHCT | 83 | |
| Progression | 13 | |
| Toxicity | 4 | |
| Ibrutinib and venetoclax treated | n = 17 | |
| Ibrutinib → venetoclax | 88 | 17 |
| Progression on ibrutinib | 80 | 15 |
| Venetoclax → ibrutinib | 12 | 17 |
| Progression on venetoclax | 100 | 2 |
| Progression on both agents | 13 | 16 |
| Progression on at least 1 agent | 82 | 17 |
| Pre-alloHCT CLL-directed therapy . | Proportion, % or median (range) . | No. with available data (total N = 65) . |
|---|---|---|
| Lines of therapy | 3 (1-9) | 65 |
| Prior NAs | 1 (1-3) | 65 |
| 2 or more NAs | 38 | 65 |
| Exclusively NAs | 29 | 63 |
| Prior ibrutinib | 82 | 65 |
| Prior venetoclax | 40 | 65 |
| Prior PI3Ki | 20 | 65 |
| Prior chemotherapy | 71 | 63 |
| Ibrutinib: response and reasons for discontinuation | n = 53 | |
| Best response: CR, PR/PR-L, SD, PD | 6, 86, 4, 4 | 50 |
| Months from ibrutinib initiation to next line of therapy | 9 (2-48) | 50 |
| Reasons for discontinuation | 52 | |
| Planned alloHCT | 62 | |
| Progression | 29 | |
| Toxicity | 6 | |
| Other | 3 | |
| Venetoclax: response and reasons for discontinuation | n = 26 | |
| Best response: CR, PR/PR-L, SD, PD | 50, 42, 4, 4 | 24 |
| Months from venetoclax initiation to next line of therapy | 6 (1-38) | 24 |
| Reasons for discontinuation | 24 | |
| Planned alloHCT | 83 | |
| Progression | 13 | |
| Toxicity | 4 | |
| Ibrutinib and venetoclax treated | n = 17 | |
| Ibrutinib → venetoclax | 88 | 17 |
| Progression on ibrutinib | 80 | 15 |
| Venetoclax → ibrutinib | 12 | 17 |
| Progression on venetoclax | 100 | 2 |
| Progression on both agents | 13 | 16 |
| Progression on at least 1 agent | 82 | 17 |
PR/PR-L, partial response or partial response with lymphocytosis.